Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials

ConclusionsSodium-glucose cotransporter inhibitors  significantly reduced major adverse cardiovascular events, including hospitalization and all-cause mortality in patients with or without established atherosclerotic cardiovascular disease. We observed a beneficial trend in patients with heart failure with preserved ejection fraction, and no benefi ts in patients with stroke or myocardial infarction.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research